Beyond DNA repair: the novel immunological potential of PARP inhibitors.

Loading...
Thumbnail Image

Embargo End Date

Authors

Chabanon, RM
Soria, J-C
Lord, CJ
Postel-Vinay, S

Document Type

Journal Article

Date

2019-01-01

Date Accepted

2019-02-18

Abstract

Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations, might mediate their therapeutic effects by potentiating anti-tumor immunity.

Citation

Molecular & cellular oncology, 2019, 6 (2), pp. 1585170 - ?

Source Title

Publisher

TAYLOR & FRANCIS INC

ISSN

2372-3556

eISSN

2372-3556

Research Team

Gene Function

Notes